recombinant human ccl2 Search Results


recombinant ccl2 protein  (R&D Systems)
95
R&D Systems recombinant ccl2 protein
Recombinant Ccl2 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant ccl2 protein/product/R&D Systems
Average 95 stars, based on 1 article reviews
recombinant ccl2 protein - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
human recombinant mcp 1  (R&D Systems)
94
R&D Systems human recombinant mcp 1
Human Recombinant Mcp 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant mcp 1/product/R&D Systems
Average 94 stars, based on 1 article reviews
human recombinant mcp 1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
monocyte chemotactic protein 1  (R&D Systems)
95
R&D Systems monocyte chemotactic protein 1
Monocyte Chemotactic Protein 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monocyte chemotactic protein 1/product/R&D Systems
Average 95 stars, based on 1 article reviews
monocyte chemotactic protein 1 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
recombinant human ccl2 protein  (R&D Systems)
99
R&D Systems recombinant human ccl2 protein
Figure 3. <t>CCL2</t> expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of <t>recombinant</t> CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.
Recombinant Human Ccl2 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human ccl2 protein/product/R&D Systems
Average 99 stars, based on 1 article reviews
recombinant human ccl2 protein - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
human ccl2 mcp 1  (R&D Systems)
92
R&D Systems human ccl2 mcp 1
Figure 3. <t>CCL2</t> expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of <t>recombinant</t> CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.
Human Ccl2 Mcp 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ccl2 mcp 1/product/R&D Systems
Average 92 stars, based on 1 article reviews
human ccl2 mcp 1 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
ccl2 mucin stalk chimera  (R&D Systems)
90
R&D Systems ccl2 mucin stalk chimera
Figure 3. <t>CCL2</t> expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of <t>recombinant</t> CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.
Ccl2 Mucin Stalk Chimera, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccl2 mucin stalk chimera/product/R&D Systems
Average 90 stars, based on 1 article reviews
ccl2 mucin stalk chimera - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
279 mc  (R&D Systems)
93
R&D Systems 279 mc
Figure 3. <t>CCL2</t> expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of <t>recombinant</t> CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.
279 Mc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/279 mc/product/R&D Systems
Average 93 stars, based on 1 article reviews
279 mc - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
exposedrecombinant human monocyte chemotactic protein 1  (R&D Systems)
86
R&D Systems exposedrecombinant human monocyte chemotactic protein 1
Figure 3. <t>CCL2</t> expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of <t>recombinant</t> CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.
Exposedrecombinant Human Monocyte Chemotactic Protein 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/exposedrecombinant human monocyte chemotactic protein 1/product/R&D Systems
Average 86 stars, based on 1 article reviews
exposedrecombinant human monocyte chemotactic protein 1 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
recombinant human ccl3  (ProSpec)
90
ProSpec recombinant human ccl3
Figure 3. <t>CCL2</t> expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of <t>recombinant</t> CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.
Recombinant Human Ccl3, supplied by ProSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human ccl3/product/ProSpec
Average 90 stars, based on 1 article reviews
recombinant human ccl3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ccl2 chemokine  (ImmunoTools)
90
ImmunoTools ccl2 chemokine
Figure 3. <t>CCL2</t> expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of <t>recombinant</t> CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.
Ccl2 Chemokine, supplied by ImmunoTools, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccl2 chemokine/product/ImmunoTools
Average 90 stars, based on 1 article reviews
ccl2 chemokine - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Figure 3. CCL2 expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of recombinant CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.

Journal: Scientific reports

Article Title: Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma.

doi: 10.1038/s41598-023-46968-2

Figure Lengend Snippet: Figure 3. CCL2 expression from neuroblastoma cells and monocytes. (A) Utilizing four neuroblastoma cell lines (SH-SY5Y, CHLA-255, NGP, SMS-KCNR), neuroblastoma cells were co-cultured with monocytes, and CCL2 protein expression was measured by ELISA. Co-culture of neuroblastoma cells and monocytes leads to higher CCL2 expression compared to either alone. (B) To determine the primary source of CCL2 protein expression, monocytes were co-cultured with neuroblastoma supernatant and neuroblastoma cells were co-cultured with monocyte supernatant. Monocytes appear to contribute more CCL2 expression than neuroblastoma cells. Experiments were performed in quadruplicate for each cell line. Student’s t-test of log 10 transformed data was performed; errors bars represent mean ± SEM. The effect of CCL2 and anti-CCL2 antibody on neuroblastoma cells. (C) Cytotoxicity assays were performed on three neuroblastoma cell lines (SH-SY5Y-Fluc, CHLA-255-Fluc, NGP-Fluc) and incubated for 24 h and 48 h (D) in varying concentrations of recombinant CCL2, with and without anti-CCL2 antibody. The addition of CCL2, with and without anti-CCL2 antibody, did not affect neuroblastoma cell survival (p > 0.5 for all). ANOVA was performed; bar graphs and errors bars represent mean ± SEM.

Article Snippet: Recombinant human CCL2 protein was obtained from R&D Systems (Minneapolis, MN, USA, Cat # 279-MC050).

Techniques: Expressing, Cell Culture, Enzyme-linked Immunosorbent Assay, Co-Culture Assay, Transformation Assay, Incubation, Recombinant

Figure 5. Combination therapy of anti-CCL2 antibody and etoposide improves survival in mice following surgical resection of primary tumors created from CHLA-255-Fluc (A), NGP-Fluc (B), and PDX (COG-N- 415X) (C). Kaplan–Meier survival plots shown here; differences in survival between groups were analyzed with linear regression.

Journal: Scientific reports

Article Title: Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma.

doi: 10.1038/s41598-023-46968-2

Figure Lengend Snippet: Figure 5. Combination therapy of anti-CCL2 antibody and etoposide improves survival in mice following surgical resection of primary tumors created from CHLA-255-Fluc (A), NGP-Fluc (B), and PDX (COG-N- 415X) (C). Kaplan–Meier survival plots shown here; differences in survival between groups were analyzed with linear regression.

Article Snippet: Recombinant human CCL2 protein was obtained from R&D Systems (Minneapolis, MN, USA, Cat # 279-MC050).

Techniques:

Figure 6. Combination treatment of etoposide with anti-CCL2 Ab decreases tumor burden in NOD-SCID gamma mice (NSG) injected with neuroblastoma (CHLA-255-Fluc and NGP-Fluc) in a minimal residual disease mouse model of neuroblastoma. (A) Following tumor resection of CHLA-255-Fluc orthotopic xenografts, mice were divided into four treatment groups (control, anti-CCL2 antibody alone, etoposide alone, and combination of etoposide and anti-CCL2 antibody) and underwent weekly bioluminescent imaging to measure tumor burden over time. (B) Combination therapy of anti-CCL2 Ab and etoposide led to significantly decreased tumor burden compared to untreated control. (C) Repeat experiment utilizing the NGP-Fluc neuroblastoma cell line. (D) Combination therapy of anti-CCL2 Ab and etoposide demonstrated decreased tumor burden compared to control. Interval regression was performed and line graphs with errors bars represent mean ± SD.

Journal: Scientific reports

Article Title: Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma.

doi: 10.1038/s41598-023-46968-2

Figure Lengend Snippet: Figure 6. Combination treatment of etoposide with anti-CCL2 Ab decreases tumor burden in NOD-SCID gamma mice (NSG) injected with neuroblastoma (CHLA-255-Fluc and NGP-Fluc) in a minimal residual disease mouse model of neuroblastoma. (A) Following tumor resection of CHLA-255-Fluc orthotopic xenografts, mice were divided into four treatment groups (control, anti-CCL2 antibody alone, etoposide alone, and combination of etoposide and anti-CCL2 antibody) and underwent weekly bioluminescent imaging to measure tumor burden over time. (B) Combination therapy of anti-CCL2 Ab and etoposide led to significantly decreased tumor burden compared to untreated control. (C) Repeat experiment utilizing the NGP-Fluc neuroblastoma cell line. (D) Combination therapy of anti-CCL2 Ab and etoposide demonstrated decreased tumor burden compared to control. Interval regression was performed and line graphs with errors bars represent mean ± SD.

Article Snippet: Recombinant human CCL2 protein was obtained from R&D Systems (Minneapolis, MN, USA, Cat # 279-MC050).

Techniques: Injection, Control, Imaging